Kura Oncology (KURA) Shares Outstanding (Diluted Average) (2020 - 2026)

Kura Oncology (KURA) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $88.6 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 1.37% year-over-year to $88.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.6 million (up 1.37% YoY) and the FY2025 annual result came in at $87.7 million, up 1.76% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $88.6 million in Q1 2026 per KURA's latest filing, from $87.7 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $88.6 million in Q1 2026 and bottomed at $66.6 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $83.9 million (2024), against an average of $78.7 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) gained 0.59%; it then advanced 24.13% in 2024.
• Tracing KURA's Shares Outstanding (Diluted Average) over 5 years: stood at $67.0 million in 2022, then advanced by 9.31% to $73.2 million in 2023, then climbed by 17.66% to $86.2 million in 2024, then increased by 1.76% to $87.7 million in 2025, then climbed by 1.07% to $88.6 million in 2026.
• Per Business Quant, the three latest KURA Shares Outstanding (Diluted Average) figures stand at $88.6 million (Q1 2026), $87.7 million (Q4 2025), and $87.6 million (Q3 2025).

Peer Comparison